HER2 억제제 시장(2025-2032년) : 치료별, 용도별, 최종 사용자별, 지역별 규모, 점유율 및 성장 분석과 산업 예측

Global HER2 Inhibitors Market size was valued at USD 9.2 billion in 2023 and is poised to grow from USD 10.14 billion in 2024 to USD 22.05 billion by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

The rising prevalence of breast and gastric cancers, particularly HER2-positive variants, is driving the global demand for HER2 inhibitors, crucial for targeted cancer therapies. These aggressive cancers exhibit lower survival rates, prompting an increase in precision treatments aimed at improving patient outcomes. Advancements in diagnostic technologies such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are enhancing early detection, further elevating the use of HER2 inhibitors. Concurrently, the introduction of new antibody-drug conjugates (ADCs) and biosimilars is reducing drug costs and expanding access to vital care. Regulatory support from the U.S. FDA and EMA, alongside expedited approval pathways for HER2-targeted therapies, is bolstering clinical development, positioning HER2 inhibitors as a focal point in oncology portfolios and driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HER2 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HER2 Inhibitors Market Segments Analysis

Global HER2 Inhibitors Market is segmented by Treatment, Application, End User and region. Based on Treatment, the market is segmented into Monotherapy and Combination Therapy. Based on Application, the market is segmented into Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer and Other Applications. Based on End User, the market is segmented into Hospitals, Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HER2 Inhibitors Market

The rising incidence of HER2-positive cancers, particularly in breast and gastric cancer cases, significantly drives the growth of the global HER2 inhibitors market. Enhanced education and awareness, alongside advancements in diagnostic capabilities, have led to improved early detection rates, resulting in a larger pool of patients requiring HER2-targeted therapies. This expanding patient demographic is not only increasing the market share for HER2 inhibitors globally but is also fueling the ongoing demand for improved and innovative HER2 inhibitor treatments within healthcare systems worldwide. Consequently, the need for advanced therapies continues to rise, further establishing the significance of this market segment.

Restraints in the Global HER2 Inhibitors Market

The Global HER2 Inhibitors market faces significant constraints primarily due to the high costs associated with these therapies. Although HER2 inhibitors offer substantial clinical benefits, their exorbitant prices severely limit access, especially in low- and middle-income countries. This financial burden affects healthcare systems and patients alike, creating a significant barrier to accessing these potentially life-saving treatments. Consequently, the high treatment costs hinder market growth and impede equitable access to advanced oncological therapies on a global scale. As a result, the potential for widespread adoption and improved patient outcomes remains significantly restricted.

Market Trends of the Global HER2 Inhibitors Market

The global HER2 inhibitors market is witnessing significant growth, propelled by advancements in targeted therapy and the rise of personalized medicine. Innovative HER2 inhibitors are being developed with enhanced specificity and efficacy, tailored specifically for HER2-positive cancers. This evolution not only aims to improve patient outcomes but also seeks to minimize adverse side effects associated with conventional treatments. The increasing prevalence of HER2-positive tumors, coupled with a growing emphasis on individualized treatment plans, is driving demand for these therapeutics. As a result, pharmaceutical companies are intensifying research and development efforts, further shaping the landscape of the HER2 inhibitors market for the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global HER2 Inhibitors Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Monotherapy
  • Single-Agent HER2 Inhibitors
  • Targeted HER2 Therapies
• Combination Therapy
  • HER2 Inhibitors Combined With Chemotherapy
  • HER2 Inhibitors Combined With Targeted Therapies
  • HER2 Inhibitors Combined With Hormonal Therapies

Global HER2 Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Squamous Cell Carcinoma
• Adenocarcinoma
• Large Cell Carcinoma
• Breast Cancer
• Other Applications

Global HER2 Inhibitors Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Other End Users

Global HER2 Inhibitors Market Size & CAGR (2025-2032)

• North America (Treatment, Application, End User)
  • US
  • Canada
• Europe (Treatment, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Genentech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Symbio Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Puma Biotechnology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipca Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations